NOVATRIX PHARMA
ActiveNOVATRIX PHARMA has been active since 2025 and the Belgian State Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €198k and a net result of €48k. Its solvency ranks better than 84% of 3181 sector peers (fiscal year 2025). The computed 12-month bankruptcy probability is 0.4% (very low).
Checked score
Score 2025
87
/ 100
Excellent
The score weighs solvency, liquidity and profitability. Bankruptcy probability contributes 35%. Every signal that weighs is under Signals.
Axes
Profitability92
Solvency100
Growth-
Track record67
Bankruptcy probability, 12 months
0.4%
Very low
0%0.5%1.5%4%10%≥ 25%
Credit up to €17k at 30 days only on tighter terms
Liquidity ample (current ratio 5.74; short-term debt: 9.4% and cash: 16.2% of total assets), and 9.4% of the assets are financed with debt.
Credit advice for your own amount and term
Signals
Seven signals. The signal on the left, the evidence on the right.
−lowers risk+raises risk○neutral
lowers risk · Lower-failure-rate sector
In this sector companies fail less often than the Belgian average.
Gazette · bankruptcies per sector, NACE 70
Relative position
BE, all sectors
reference
Sector 70
lower
← fewer bankruptcies
more bankruptcies →
raises risk · Young company
A young company has little track record yet and statistically fails more often than an established one.
KBO · incorporation dateAge against the risk zone
lowers risk · Annual accounts: healthy financial profile
The latest annual accounts show a healthy profile in solvency, result and liquidity.
NBB · annual accounts 2025Solvency, return and age of the figures
Solvency
90.6%
Return on assets
21.8%
Age of the figures
9 mo
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 30-06-2026, 31 days ahead of the deadline.
NBB · 1 filingDeviation from the deadline
2025
31 d early
← before the deadline
after the deadline →
Financials · fiscal year 2025, full schema
Turnover
Not included in this filing
EBIT margin
Not included in this filing
Net result
€48k
Working capital
€98k
Balance-sheet composition
Assets €218k
Fixed assets
€100k
Current assets
€118k
Equity and liabilities €218k
Equity
€198k
Debt
€21k
Debt finances 9.4% of the balance-sheet total.
Key figures and ratios
Solvency
90.6%
Current ratio
5.74
Quick ratio
5.74
Debt / equity
0.10
ROE
24.1%
ROA
21.8%
Debt
€21k
Debt ≤ 1 year
€21k
Income taxes
€12k
Filed annual accounts
As filed with the NBB · 2025
Balance sheet
Code2025
Assets
Total assets20/58€218k
Fixed assets21/28€100k
Financial fixed assets28€100k
Current assets29/58€118k
Amounts receivable within one year40/41€83k
Trade receivables40€33k
Other amounts receivable41€50k
Cash at bank and in hand54/58€35k
Equity and liabilities
Total equity and liabilities10/49€218k
Equity10/15€198k
Contributions10/11€150k
Capital10€150k
Issued capital100€150k
Reserves13€2k
Non-distributable reserves130/1€2k
Legal reserve130€2k
Profit (loss) carried forward14€45k
Amounts payable17/49€21k
Amounts payable within one year42/48€21k
Trade debts44€2k
Suppliers440/4€2k
Taxes, remuneration and social security45€19k
Taxes450/3€19k
Other amounts payable47/48€18
Income statement
Code2025
Gross operating margin9900€60k
Operating profit (loss)9901€60k
Financial charges65/66B€17
Recurring financial charges65€17
Profit (loss) for the period before taxes9903€60k
Income taxes67/77€12k
Profit (loss) for the period9904€48k
Profit (loss) for the period to be appropriated9905€48k
Appropriation of the result
Profit (loss) to be appropriated9906€48k
Transfer to equity691/2€2k
To the legal reserve6920€2k
The notes to these accounts (5 items: statements of assets and debts, cost breakdowns, rights and commitments) are not shown here.
Timeline · acts, filings and financial milestones
2026
30-06
NBB filing
Annual accounts filed
fiscal year 2025 · full schema
NBB filing
Directors · office · real estate
Directors
1 act for this company is in the Belgian State Gazette, of which we have read 0. We have therefore not extracted its directors from those acts yet.
Location & real-estate footprint
Registered office, Schaarbeek · 1 establishment unit since 2025
Cannot be placed on the map
This address could not be matched to a point in the Belgian address register (BOSA BEST). The address below comes straight from the Crossroads Bank.
Brabançonnelaan 1391030 SchaarbeekGround area
119 m²
Building footprint
113 m²
Volume, LiDAR
1,656 m³
Parcel 21905C0057/00C005, Brussels · tallest building 16.2 m, ±5 floors. Linked by address, not a title deed.
1 establishment unit
NOVATRIX PHARMA
since 20252.375.928.589
1 parcel
Brussels
1
(100%)
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 21905C0057/00C005 | Brussels | 119 m² | 1 · 113 m² | 16.2 m · 5 fl. |
Linked by address, not proof of ownership
Methodology
via registered seat: 1
1 of 1 parcel with an exact address match; the rest are indicative.
Linked through address data, this is not proof of ownership.
Similar companies · same sector, comparable size
I.M.C.
BE 0474.091.854
Stekene · Eq €198k
Vermiljoen
BE 0466.588.707
Brasschaat · Eq €198k
WENGE
BE 0893.520.448
Tournai · Eq €198k
ChocNmore
BE 0785.440.969
Lier · Eq €198k
Zilos
BE 0794.453.457
Mol · Eq €198k
Of 82,570 companies in sector 70200 we hold annual accounts for 52,573. 40,098 are within a factor 10 of this equity.See the whole sector
Company data · Crossroads Bank
Identification
Legal formPublic limited company
Founded18-07-2025
Fiscal year end31-12
Activities, NACEBEL
70200Business and other management consultancy
Sources
Crossroads Bank for EnterprisesNational Bank · 1 filingAddress and cadastre registers
Data from official sources, last processed on 19-09-2026. Scores and ratios are computed by Checked and are not a credit decision.